We are proud to present the 6th Annual
AI in Drug Discovery Conference on 10th-11th March 2025, in London, UK. Join us for the biggest
AI in drug discovery event in the UK, that brings together the highest number of big pharma speakers for focused discussions and networking.
With the global
AI in drug discovery market expected to reach 7.94 billion by 2030, AI is leading technological advancement across the pharmaceutical sector, and is expected to transform pre-clinical drug discovery.
Are you ready for this transformative period?
With ever-increasing pressures on drug pipelines, strategies for faster, cheaper and more successful R&D are required - this conference will showcase how AI-driven technologies are turning these strategies into reality. Through detailed case-study presentations and interactive panel-discussion sessions, we will navigate data volume and quality challenges, create strategies for increasing efficiency of R&D, and explore the impact of generative AI on drug discovery pipelines.
This year's event will feature hot topics including applications of AI for precision medicine, ML-driven target identification and optimization, the impact of generative AI on ways of working and conducting in silico clinical trials.
Our two-day agenda offers you peer-to-peer networking with industry experts from an extensive selection of big pharma and breakthrough biotech's in the field, including directors and heads of informatics, data & AI, molecular design, and computational chemistry. Don't miss the chance to hear the latest advancements from leaders in the industry!
Benefits of attending:
- ENGAGE in case study presentations and panel discussions from an extensive number of big pharma leaders and decision-makers addressing the impact of generative AI, and in-silico modelling on success rates within early R&D.
- UNDERSTAND how AI can accelerate drug discovery timelines and reduce costs across the pipeline from discovery to trials.
- DELVE into best practices in data quality, privacy and regulatory considerations
- EXPLORE how AI is being used to drive precision medicine, and enable targeting of previously undruggable diseases
Featured Speakers
- Christoph Grebner, Senior Principal Scientist, Sanofi
- Fabian Heinemann, Lead of IT Data Science Chapter, Boehringer Ingelheim
- Florian Nigsch, Director Data Science, Novartis
- Fred Manby, Co-Founder and CTO, Iambic Therapeutics
- Hannah Bruce Macdonald, Associate Principal Scientist, CHARM Therapeutics
- Henrik Moebitz, Director, CADD, Global Discovery Chemistry, Novartis
- James Lumley, Head of Cheminformatics, GSK
- Kinga Bercsenyi, Chief Business Officer, Arctoris
- Le Mu, Product Line Manager for End-to-End AI/ML, Product Owner and Tech Lead for Roche pRED-MLOps service, Roche
- Lewis Vidler, Senior Director - Structure Based Drug Design, Eli Lilly
- Lisa Schneider, Machine Learning Scientist, Bayer
- Marcel Verdonk, Research Fellow, Astex Pharmaceuticals
- Maureen Makes, VP Engineering, Recursion
- Peter Clark, VP, Computational Drug Design, Novo Nordisk
- Petrina Kamya, President, Insilico Medicine Canada Inc., and Global Head of AI Platforms, VP, Insilico Medicine
- Prakash Rathi, Augmented Drug Design Engineering Lead, AstraZeneca
- Ravi Gupta, Advisor - Clinical Data Automation, Data & Analytics, Eli Lilly & Company
- Steve Gardner, CEO, PrecisionLife
- Vladislav Kim, Research Scientist, Bayer
- Yogesh Sabnis, Director of Lead Design, UCB Biopharma srl
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK
